Nuwellis has installed three Aquadex SmartFlow Systems at a pediatric healthcare provider in Michigan, marking its first pediatric program in the state. This installation expands Nuwellis' growing presence in pediatric critical care into a significant healthcare market. The systems are designed to provide controlled, predictable fluid removal for patients suffering from fluid overload, a critical need in pediatric care settings.

The new installations support the development of clinical protocols and workflows to integrate Aquadex therapy into the hospital's pediatric care program. This integration creates a foundation for future consumable utilization and long-term growth. Clinicians are increasingly adopting Aquadex therapy in pediatric and critical care settings, highlighting its strategic importance for Nuwellis.

Pediatric programs represent a key growth opportunity for Nuwellis to broaden access to Aquadex therapy. By expanding into this segment, the company aims to strengthen its leadership position in the fluid management category. The Michigan installation is part of Nuwellis' broader strategy to prioritize expansion within pediatric and critical care markets.

The Aquadex SmartFlow System is a critical tool for managing fluid overload in pediatric patients. Its adoption underscores the growing demand for advanced fluid management solutions in specialized care environments. Nuwellis' focus on pediatric programs aligns with its mission to improve patient outcomes through innovative therapy options.

Nuwellis, Inc. has appointed Mike McCormick as its new Chief Executive Officer, effective June 30, 2026, as part of a strategic leadership transition. John Erb will step down from executive responsibilities but will remain with the company as Chairman of the Board. The announcement was detailed in a Letter to Shareholders reviewing the company's year-to-date performance and outlining future priorities.

Leadership Transition Details

The appointment marks a significant shift in the executive structure of the medical technology company. McCormick, who assumes the role on June 30, 2026, will lead the organization focused on delivering solutions for patients with cardiorenal conditions. Erb's continued presence as Chairman provides stability during the transition period.

Strategic Priorities

The leadership transition accompanies a review of the company's year-to-date performance. Nuwellis remains committed to its core mission in the medical technology sector, specifically targeting cardiorenal conditions. The new CEO is expected to drive the strategic priorities outlined in the shareholder communication.